Efficacy of Direct-Acting anti-viral Therapy on Fatty Liver Di-sease in Patients with the diag-nose of Hepatitis C genotype 3

Abstract

Non-Alcoholic Fatty Liver Disease and Insulin resistance in patients with hepatitis C are the significant determinants of the progression of liver fibrosis and virological response to antiviral therapy. The aim of the study was to assess the prevalence of steatosis and the stage of Fibrosis in Patients with chronic hepatitis C with genotype 3 who achieved a sustained virological response (SVR) after Direct –Acting antiviral therapy (DAA). 75 Patients with chronic hepatitis C with Genotype 3 were included in the study. The Patients had been treated for 12 weeks with Ledipasvir/Sofosbuvir (Harvoni) + Ribavirin; SVR was achieved in 70 patients. Transient Elastography [Fibroscan 502] with controlled attenuation parameter (CAP) was used to assess hepatic steatosis; According to our study majority of patients with chronic hepatitis C with genotype 3 had steatosis. In patients with genotype 3 steatosis was in correlation with viral load. After achieving SVR steatosis significantly decreas